Cytosorbents Corporation develops and commercializes extracorporeal blood purification systems designed to remove inflammatory mediators and other harmful substances from patient blood. The company's core technology platform employs proprietary adsorbent and porous polymer materials integrated into cartridge-based devices. Its primary product, CytoSorb, targets patients undergoing cardiothoracic surgery or experiencing severe systemic inflammation, sepsis, and organ failure. The company also markets DrugSorb-ATR for antithrombotic drug removal and is developing HemoDefend-BGA to reduce blood group antibodies in transplant patients.
The product portfolio extends beyond human applications. VetResQ addresses septic shock, toxin-mediated diseases, and trauma in veterinary medicine. The company is advancing additional platforms including PuriFi, a hemoperfusion pump system, and ECOS-300CY, an ex vivo organ perfusion device intended to preserve harvested organs for transplantation.
Based in Princeton, New Jersey, Cytosorbents operates with approximately 149 full-time employees and maintains a commercial presence in Germany and internationally. The company is incorporated in Delaware and trades on the Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.38 | $-0.38 | -216.7% | |
| 2023 | $-0.12 | $-0.12 | -500.0% | |
| 2022 | $-0.02 | $-0.02 | +88.9% | |
| 2021 | $-0.18 | $-0.25 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | $-0.08 | $-0.08 | +0.0% | |
| 2015 | $-0.08 | $-0.08 | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-31 | 0001410578-25-000591 | SEC ↗ |
| 2023-12-31 | 2024-03-15 | 0001410578-24-000201 | SEC ↗ |
| 2022-12-31 | 2023-03-09 | 0001410578-23-000234 | SEC ↗ |
| 2021-12-31 | 2022-03-10 | 0001410578-22-000331 | SEC ↗ |
| 2020-12-31 | 2021-03-09 | 0001104659-21-033790 | SEC ↗ |
| 2019-12-31 | 2020-03-05 | 0001104659-20-029712 | SEC ↗ |
| 2018-12-31 | 2019-03-07 | 0001144204-19-012774 | SEC ↗ |
| 2017-12-31 | 2018-03-08 | 0001144204-18-013618 | SEC ↗ |
| 2016-12-31 | 2017-03-03 | 0001144204-17-012631 | SEC ↗ |
| 2015-12-31 | 2016-03-09 | 0001144204-16-086916 | SEC ↗ |
| 2014-12-31 | 2015-03-31 | 0001144204-15-020124 | SEC ↗ |
| 2013-12-31 | 2014-03-31 | 0001144204-14-019382 | SEC ↗ |
| 2012-12-31 | 2013-04-03 | 0001144204-13-019816 | SEC ↗ |
| 2011-12-31 | 2012-03-30 | 0001144204-12-018905 | SEC ↗ |
| 2010-12-31 | 2011-03-31 | 0001144204-11-018583 | SEC ↗ |
| 2009-12-31 | 2010-04-09 | 0001144204-10-019399 | SEC ↗ |
| 2008-12-31 | 2009-04-10 | 0001144204-09-019971 | SEC ↗ |